CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Blood

Volumn 123, Issue 15, 2014, Pages 2416-2419

  Rumi, Elisa ^a,b   Harutyunyan, Ashot S ^c   Pietra, Daniela ^a   Milosevic, Jelena D ^c   Casetti, Ilaria C ^b   Bellini, Marta ^b   Them, Nicole C C ^c   Cavalloni, Chiara ^a   Ferretti, Virginia V ^a   Milanesi, Chiara ^a   Berg, Tiina ^c   Sant'Antonio, Emanuela ^b   Boveri, Emanuela ^a   Pascutto, Cristiana ^a   Astori, Cesare ^a   Kralovics, Robert ^c,d   Cazzola, Mario ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2; THROMBOPOIETIN RECEPTOR; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN;

ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLONAL VARIATION; COMPARATIVE STUDY; DISEASE COURSE; ERYTHROCYTOSIS; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENOTYPE; GRANULOCYTE; HUMAN; INDEL MUTATION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PEDIGREE ANALYSIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SOMATIC MUTATION; SURVIVAL RATE; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; X CHROMOSOME INACTIVATION; EXON; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PEDIGREE;

CALRETICULIN; DNA MUTATIONAL ANALYSIS; EXONS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; MUTATION; PEDIGREE; PHENOTYPE; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84901777448     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-550434     Document Type: Article

References (24)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
2. Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007;25(35):5630-5635.
3. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346-352. (Pubitemid 43990648)
4. Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107(9):2206-2211. (Pubitemid 44665655)
5. Olcaydu D, Rumi E, Harutyunyan A, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011;96(3):367-374.
6. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200. (Pubitemid 38685363)
7. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003-2007.
8. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42(9):794-800.
9. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379- 2390.
10. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
11. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes [published online ahead of print December 23, 2013]. Blood.
12. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17):3538-3545.
13. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686-1689. (Pubitemid 351213460)
14. Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607-611.
15. Rumi E, Pietra D, Guglielmelli P, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121(21):4388-4395.
16. Rumi E, Harutyunyan AS, Casetti I, et al. A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol. 2014;89(1):117-118.
17. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554. (Pubitemid 9067879)
18. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12(8):737-751. (Pubitemid 23134304)
19. Mead AJ, Chowdhury O, Pecquet C, et al. Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood. 2013;121(20):4156-4165.
20. Marty C, Saint Martin C, Pecquet C, et al. Germline JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors [published online ahead of print January 7, 2014]. Blood.
21. Skoda RC. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009;159-167.
22. Percy MJ, Rumi E. Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. Am J Hematol. 2009;84(1):46-54.
23. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia [published online ahead of print December 26, 2013]. Blood.
24. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons [published online ahead of print January 9, 2014]. Leukemia.